← Back to Treatments
🏅 FDA Orphan Designation

Hivid

Zalcitabine

Manufacturer: Hoffmann-La Roche, Inc.

Indicated for:
AA amyloidosisOrphanCongenital Epstein-Barr virus infection

FDA-Approved Indications (2)

AA amyloidosisOrphan Designation

Combination therapy with zidovudine is indicated for the treatment of adult patients with advanced HIV infection (CD4 count < 300) who have demonstrated malignant clinical or immunologic deterioration…

Combination therapy with zidovudine is indicated for the treatment of adult patients with advanced HIV infection (CD4 count < 300) who have demonstrated malignant clinical or immunologic deterioration…

Population: adults with CD4 count < 300

Indications & Usage

Combination therapy with zidovudine is indicated for the treatment of adult patients with advanced HIV infection (CD4 count < 300) who have demonstrated malignant clinical or immunologic deterioration.

💙 Support Programs

View all →
Hivid
Hoffmann-La Roche, Inc.
Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.